摘要:
Cough is a common experience and the most frequent reason why an individual seeks a visit to a physician. The prevalence of cough is about 10+% of the population. Cough is a manifestation of many aerodigestive tract disorders and especially consequential for serious lower airway diseases such as respiratory infections, chronic obstructive pulmonary disease (COPD) and asthma because increased coughing leads to emergency room visits and hospitalization. There is a need for methods to oversee coughing frequency in certain patients. Traditionally, all automated cough monitors have used cough sound as the signal for the measurement of cough. In the present invention movements of the diaphragm muscle, recorded by a motion sensor placed above the xiphoid process, are used for counting coughs. A device for such recordings is described and data were collected. This method is validated by using citric acid spray to trigger cough sounds and to show that the provoked acoustic signal is matched by the electronic signals from the movement sensors. The xiphoid process is a unique anatomical landmark for the non-acoustic detection of cough.
摘要:
The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-5, DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”, that are useful, for example, in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; dermatitis; ocular pain and discomfort; heat discomfort; heat stress; flushing and/or night sweats (vasomotor symptoms); post-operative hypothermia; post-anaesthetic shivering; nasal congestion and nasal obstruction; pharyngeal and esophageal discomfort; fatigue; tiredness; depression; cognitive dysfunction; and to enhance cognitive function. The applicant has found that localized delivery of DIPA compounds to the upper eyelid and/or facial skin has an alerting and enhancement effect on behavior and can be used to give a cosmetic refreshing look, to mental alertness, to reduce fatigue, and to improve work output. The present discovery also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy, in diagnosis of neuropathic pain, and in study of TRPM8 function.
摘要:
Short-chain 2- to 3-carbon alcohols are used as solvents for cooling agents in the preparation of topical therapeutic and cosmetic formulations. Some of these alcohols, especially ethanol, inhibit the ability of the cooling agent to activate its target receptor. In one embodiment of this invention, (R)-1,2-propanediol is used as an alcoholic solvent for the topical delivery of cooling agents to biological surfaces. This (R)-1,2-propanediol enantiomer has a minimum inhibitory effect on cooling with respect to standard 2- to 3-carbon alcoholic solvents, and functions to substantially protect the agents cooling activity from inhibition when in the presence of a short-chain alcohol such as ethanol.
摘要:
Administration of a Corticotropin-Releasing Factor (or a salt or analog thereof) decreases the leakage of blood components into brain tissue produced by various adverse medical conditions and reduces bleeding when muscle tissues are cut and handled, such as in plastic and reconstructive surgery. A method of treating a patient for injury to or disease of the brain, central nervous system, or musculature in which edema is a factor comprises administering to the patient a Corticotropin-Releasing Factor (or a salt or analog) in an amount effective to decrease vascular permeability in the injured or diseased brain, nervous system tissue or musculature, and thereby to reduce edema. Administration in accordance with the method can be about two hours before surgery, or can be up to three days after injury.
摘要:
Relatively small, synthetic anti-inflammatory peptides are provided having the primary sequenceT.sub.N --A.sub.1 --A.sub.2This invention was made with Government support under Grant No. DA-00091 awarded by the National Institutes of Health. The Government has certain rights in this invention.
摘要:
A method is provided for treating high blood pressure and disturbances of cardiac function by administering a therapeutically effective dosage of dynorphin-related opioid peptides, such as dynorphin(1-13) and dynorphin(1-10) amide, having at least ten amino acids linked sequentially by peptide bonds and with the five amino acids from the N-terminal end being the same as, or mimicking, Leu-enkephalin. Administration may be over a period of time, as for individuals with chronic high blood pressure, and may be by dispensing the medicament in aerosol form.
摘要:
The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”, that are useful, for example, in the treatment of the discomforts of dermatological disorders (e.g., diseases) The treatment is for the dysesthesia (e.g., caused by irritation, itch, or pain) due to dermatitis, urticaria; scalp itch; vulvar itch; lichen sclerosus; cholestatic itch; psoriasis; sebhorrheic dermatitis; allergic conjunctivitis; blepharitis; and pruritus of the elderly. The applicant has found that topical delivery of DIPA compounds to the skin alleviates the dysesthesia of these conditions in human subjects. The present discovery pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in the treatment of the dysesthesia of these dermatological disorders.
摘要:
The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to a particular 1-di-alkyl-phosphinoyl-alkane, 1-(Diisopropyl-phosphinoyl)-nonane, referred to herein as “DIPA-1-9”. DIPA-1-9, is able to selectively treat (e.g., suppress) sensory discomfort arising from the airways without side effects. Compared to structurally similar compounds, DIPA-1-9 did not have the problems of excessive cold, stinging, or irritancy, or of adverse taste. To deliver the DIPA-1-9 to the upper airway it is formulated as a solution of DIPA-1-9 in water, a water-based solution, or syrup, at a concentration of 2 to 10 mg/mL and a delivery volume of less than 0.5 mL per unit dose. The drops of DIPA-1-9 are administered into the nasal cavity or onto the base of the tongue, next to the pillars of fauces. The DIPA-1-9 then reaches the nerve endings at the base of the epithelia and transduces signals of coolness and cold. Cooling of the upper airways relieves discomfort and is useful for conditions such as throat irritation, cough, pharyngitis, and lower airway blockage disorders. The elicitation of cooling in the upper airways can be used to control cough, to treat dyspnea, and to enhance mucus clearance in lower airway disorders such as chronic obstructive pulmonary diseases (which includes bronchitis and bronchiectasis), asthma, interstitial lung diseases, cystic fibrosis, lung fibrosis, pneumonia, and other lung disorders. The efficacy of DIPA-1-9 in treating chronic obstructive pulmonary disease is especially attractive because the four primary signs of chronic obstructive pulmonary disease, cough, excessive sputum production, dyspnea, and psychic distress from the lack of control of airway discomfort, are favorably ameliorated by topical application of DIPA-1-9 to the upper airways. This method of treating chronic obstructive pulmonary disease with a cooling agent to the upper airways has not been previously described.
摘要:
The present discovery pertains to the discovery of certain amphiphilic compounds that may be useful for the management of sebum secretion in subjects with acne, oily skin, or seborrheic dermatitis. These compounds are 1-dialkylphosphorylalkanes with the longest alkyl group being seven or more carbons. Preferably, a compound is dissolved in a dermatologically acceptable vehicle, and delivered to the skin in a solution, gel, lotion, cream, or ointment. The method of application may be with the surface of the finger, or via an applicator. The decrease is sebum secretion in certain subjects may result in skin conditions that enhance cosmetic appearance and ameliorate skin disorders.
摘要:
The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-alkyl-phosphinoyl-alkanes as described herein, DIPA-1-8 and DIPA-1-9, and 2-6 and 2-7 that are collectively referred to herein as “DAPA compounds”, that are useful in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by inflammation, irritation, itch, or pain) in the nasal cavity. The applicant has found that localized delivery of DAPA compounds with a swab to the Kiesselbach's area of the human nose will relieve the discomforts of rhinitis and other nasal cavity discomforts.